ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

40 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

CenerimodPlacebo

Viatris Innovation GmbH420 participants216 sites · United States, Argentina, BrazilCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Phase 2Phase 3Type 1 Diabetes Mellitus

Dimethyl Fumarate Enteric-coated CapsulesInsulin

Nanjing Medical University96 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

Phase 1Phase 2Severe Combined Immunodeficiency

AProArt-CD34CliniMACS® CD34 Reagent System cell sorter deviceBusulfan

University of California, San Francisco24 participants1 site · United StatesCompletes Jun 2038

Compare CT.gov Full analysis →

Recruiting

A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis

Phase 3Rheumatoid Arthritis (RA)

MB04 (proposed biosimilar to etanercept)Enbrel (etanercept)

mAbxience Research S.L.458 participants60 sites · Bulgaria, Georgia, MoldovaCompletes Oct 2025

Compare CT.gov Full analysis →

Recruiting

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Phase 2Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)

HydroxyureaAlemtuzumabFludarabine+2 more

Paul Szabolcs100 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Phase 3Immunoglobulin A Nephropathy (IgAN)

FelzartamabPlacebo

Biogen454 participants227 sites · United States, Argentina, AustraliaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Systemic Lupus Erythematosus

UpadacitinibPlacebo

AbbVie1,000 participants369 sites · United States, Argentina, AustraliaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Phase 2Systemic Lupus Erythematosus

BI 3000202Placebo

Boehringer Ingelheim405 participants132 sites · United States, Argentina, AustraliaCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Phase 3Rheumatoid Arthritis

MethotrexateAbataceptAdalimumab+13 more

University of Nebraska400 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Phase 2Phase 3Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus

LitifilimabPlacebo

Biogen450 participants314 sites · United States, Argentina, BelgiumCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Phase 2Lymphoproliferative DisordersAutoimmune LymphoproliferativeImmune System Diseases

Busulfan test doseFludarabineBusulfan+6 more

National Cancer Institute (NCI)66 participants1 site · United StatesCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Phase 1Phase 2Relapsing Polychondritis

Upadacitinibcorticosteroids and immunosuppressants

Peking University People's Hospital30 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Phase 3Psoriatic Arthritis

ZasocitinibActive ComparatorPlacebo

Takeda1,088 participants189 sites · United States, Belgium, BulgariaCompletes May 2027

Compare CT.gov Full analysis →

1–15 of 40

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

40 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Phase 3Lupus Erythematosus, Systemic

CenerimodPlacebo

Viatris Innovation GmbH420 participants216 sites · United States, Argentina, BrazilCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Phase 2Phase 3Type 1 Diabetes Mellitus

Dimethyl Fumarate Enteric-coated CapsulesInsulin

Nanjing Medical University96 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Autologous Gene Therapy for Artemis-Deficient SCID

Phase 1Phase 2Severe Combined Immunodeficiency

AProArt-CD34CliniMACS® CD34 Reagent System cell sorter deviceBusulfan

University of California, San Francisco24 participants1 site · United StatesCompletes Jun 2038

Compare CT.gov Full analysis →

Recruiting

A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis

Phase 3Rheumatoid Arthritis (RA)

MB04 (proposed biosimilar to etanercept)Enbrel (etanercept)

mAbxience Research S.L.458 participants60 sites · Bulgaria, Georgia, MoldovaCompletes Oct 2025

Compare CT.gov Full analysis →

Recruiting

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Phase 2Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)

HydroxyureaAlemtuzumabFludarabine+2 more

Paul Szabolcs100 participants1 site · United StatesCompletes Nov 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Phase 3Immunoglobulin A Nephropathy (IgAN)

FelzartamabPlacebo

Biogen454 participants227 sites · United States, Argentina, AustraliaCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

Phase 3Systemic Lupus Erythematosus

UpadacitinibPlacebo

AbbVie1,000 participants369 sites · United States, Argentina, AustraliaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Phase 2Systemic Lupus Erythematosus

BI 3000202Placebo

Boehringer Ingelheim405 participants132 sites · United States, Argentina, AustraliaCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Phase 3Rheumatoid Arthritis

MethotrexateAbataceptAdalimumab+13 more

University of Nebraska400 participants1 site · United StatesCompletes Mar 2028

Compare CT.gov Full analysis →

Recruiting

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Phase 2Phase 3Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus

LitifilimabPlacebo

Biogen450 participants314 sites · United States, Argentina, BelgiumCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Phase 2Lymphoproliferative DisordersAutoimmune LymphoproliferativeImmune System Diseases

Busulfan test doseFludarabineBusulfan+6 more

National Cancer Institute (NCI)66 participants1 site · United StatesCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Phase 1Phase 2Relapsing Polychondritis

Upadacitinibcorticosteroids and immunosuppressants

Peking University People's Hospital30 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Phase 3Psoriatic Arthritis

ZasocitinibActive ComparatorPlacebo

Takeda1,088 participants189 sites · United States, Belgium, BulgariaCompletes May 2027

Compare CT.gov Full analysis →

1–15 of 40